Kiavasch Farid
@KFHemeOnc
Followers
119
Following
3K
Statuses
144
Hematology/oncology resident @uniklinik_hd @med5_ukhd. Pianist and composer. Loves learning and teaching.
Heidelberg
Joined May 2021
RT @NEJM: An 84-year-old man with a history of melanoma of the right forehead complicated by in-transit metastases to the scalp presented t…
0
15
0
RT @BrestoffLab: Bidirectional #mitochondria transfer swaps T cell mitochondria with those from cancer cells to impair anti-tumor immunity.…
0
42
0
For those who cheered too soon - an excellent analysis of the greatly misinterpreted and spurious 'OS benefit', especially when applied to the real-world setting (at least in the USA and in europe). Props to @ajperissinotti, @Berninini and @ManniMD1!
Check out our latest episode "The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma" with @ManniMD1 @ajperissinotti and @Berninini 🦅💨 #myeloma #badblood
0
2
5
RT @abouezzeddine: Agree 💯! Regardless of ratio & IFE, elevated lambda > kappa: considered guilty until proven innocent! #lambdaparanoia @A…
0
2
0
RT @BloodJournal: Introduction to a How I Treat series on acute lymphoblastic leukemia #lymphoidneoplasia #reviewse…
0
15
0
RT @KatjaSockel: Groundbreaking paper in @TheLancet : Successful treatment of multi-refractory ITP with CD19 CAR T cells. #ITP #CAR_T
@I…
0
15
0
RT @NicoGagelmann: Beware of beta blockers🫀 Use of non-selective beta blockers impairs engraftment after BMT involving post-transplant che…
0
22
0
0
3
0
RT @FrontImmunol: New Research: GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation — successfully treated by…
0
1
0
RT @aksinghmd: I fully agree. I'm perplexed by the cognitive dissonance in the myeloma community: on one hand, every reduction in steroid d…
0
6
0
0
0
2
RT @WolverHeme: We’re BACK! Check out our latest episode, “Houston, we don’t have a problem… with APOLLO!” Is there a new standard of care…
0
7
0
RT @joshmcgoo: Always impressed how not concerned heme Onc is. “Oh she has SIX platelets now? Awesome! Hgb of 2.3 is whatever.” Madlads al…
0
50
0
@MatthewHoMD @AaronGoodman33 @nihardesai7 @dgermain21 @Eddie_Cliff @CharlesMilrod Great work as always! PMBCL seems to be missing
0
0
2
RT @AaronGoodman33: ASH Abstract Koura et al = Calcineurin free GVHD PPx Randomized phase II Abatacept+PTCy vs CNI+MTX moderate/severe cG…
0
47
0
RT @AaronGoodman33: I’m gonna call it like it is. The QUAZAR study was highly UNETHICAL. This study represents a failure of IRBs. Listen…
0
7
0
RT @BloodJournal: Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia https:/…
0
40
0
UPDATE: We chose the middle way. We decided to give a CD34-selected boost without re-starting immunosuppresion and we even discontinued all growth factors. D+22: L 3.5/nl, Hb (w/o transfusions since d0) 8.7g/dl, T 93/nl! Happy patient, happy doctor. :) Thanks to all!
0
0
2
@E_D_Bezerra @doctorpemm @Haematologica @grichardmd @TapKadia @MDAndersonNews @DrHKantarjian @kanagalshamanna @DanielleHammo20 @DrKTakahashi @GBorthakur @EJShpallMD @Daver_Leukemia @garciamanero @mkonople @GCC_Cortes According to the new WHO 2022 classification, t(3;3) is now considered AML-defining - seeing the aggressive and refractory (esp TKI-resistant) course of the pt's disease, it does indeed behave like a poor risk AML!
0
0
1